Bristol Myers Squibb says it will purchase an Nvidia DGX SuperPOD to accelerate artificial intelligence use across its drug discovery and development work. According to multiple reports, the company expects the system to support AI-based analysis and computational tasks used in researching potential therapies.
Bristol Myers Squibb also describes the move as notable because it will be the first life sciences company to acquire a DGX SuperPOD built on Nvidia’s Vera Rubin architecture. Nvidia’s Vera Rubin platform is designed to provide AI computing capabilities for large-scale workloads, and the DGX SuperPOD is presented as an integrated supercomputing system for training and deploying AI models.
The announcement is framed as part of Bristol Myers Squibb’s broader efforts to adopt advanced computing and AI technologies within pharmaceutical R&D. While the reports focus on the purchase and expected use, they do not provide detailed timelines, pricing, or specific project outcomes associated with the deployment.
